Phesi has released the results of its global analysis of all clinical trials conducted in 2021, which shows that breast cancer was the most studied disease area, followed by Covid-19. Overall, oncology dominated the top five, which also included non-small cell lung cancer, solid tumours and multiple myeloma (Figure… Read More
2022's World Cancer Day theme is “Close the Care Gap”1 and is focused on raising awareness of the cancer care equity gap that affects almost everyone, in high as well as low- and middle-income countries, and costs lives. DDW’s Megan Thomas comments on the crisis as well as initiatives that are working to close this… Read More
Novartis UK has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given a positive scientific opinion for the investigational treatment asciminib to be made available to appropriate patients under the UK Early Access to Medicines Scheme (EAMS).1 What does this mean? The… Read More
Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukaemia (AML)1 has been granted orphan-drug designation (ODD) by the European Commission (EC). What is ALM? AML is the most common form of acute… Read More
Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More
Not only is there is a severe lack of effective T-cell lymphoma (TCL) treatments, according to GlobalData, but the data and analytics company does not expect any significant solutions to appear in the next decade. Context According to GlobalData, one key unmet need is found in the… Read More
Researchers at the Francis Crick Institute, UCL, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London have developed a computer model to analyse how the way in which tumours grow affects their genetic makeup. Using this new model, they have identified links between tumour growth… Read More
According to new results published as a correspondence in Cancer Cell, nearly 100% of cancer patients with solid tumours have antibodies effective against the Delta variant after a third dose of Covid-19 vaccine. What does this mean? The new findings highlight a proportion of patients with blood… Read More
Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province. The… Read More
A RIKEN-led team has developed a new way to treat cancer that has fewer side effects than conventional drugs, which results from a targeted method for killing tumour cells in mice1. Reportedly, the novel therapeutic triggers the self-destruct programme of cancer cells by delivering a masked peptide and a catalyst… Read More
Mount Sinai researchers have reached a cancer research milestone and proven how cancer cells remain dormant for years after they leave a tumour and travel to other parts of the body, before awakening to create metastatic cancer. The findings According to findings reported in Nature Cancer,… Read More
MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases. The acquisition This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More
The National University Cancer Institute, Singapore (NCIS) and MiNA Therapeutics have dosed the first patients in an investigator-sponsored Phase I study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are… Read More
Researchers at the Francis Crick Institute and Universidade de Santiago de Compostela have identified how the hepatitis B virus (HBV) can support the survival and growth of liver cancer, with this process starting early in tumour development, in some instances up to 20 years before cancer diagnosis. Context Around… Read More
Novasep, a supplier of services and technologies for the life sciences industry, and McSAF, a French biotech specialised in bioconjugation tools to design bio drugs for health and diagnostics, have collaborated for the preclinical production of ADCITMER, a next-generation Antibody-Drug Conjugate (ADC) to treat neuroendocrine cancers. What has been done?… Read More
Terumo Blood and Cell Technologies and Immunicom have signed a co-commercialisation agreement to help advance a cancer therapy that selectively removes immune inhibitors from a patient’s bloodstream. What will this achieve? This potentially enables the patient’s immune system to more effectively attack cancer tumours. In contrast to immunotherapy pharmaceuticals… Read More
